Express Pharma Private Limited - Due diligence report

A 360° intelligence report on Express Pharma Private Limited: trust score, financial health, credit view, compliance, directors, growth and …

2005-03-16 Mumbai, Maharashtra Strike Off Unlisted Active Compliant
Share
View plans
EP Express Pharma Private Limited
Full Due-Diligence Report + Documents
  • Unlock all financial figures & 5-year trends
  • Full trust, health & credit-risk scores
  • Director details, charges & MCA documents
₹700 ₹349 50% off New user
Or enjoy up to 50% off with credits View credit packages
Company Credits – Starter
  • One credit unlocks this full due-diligence report
  • Use across any company’s report, anytime
  • Credits valid for 12 months
× ₹700 ₹279 = ₹2,790 60% off
Choose your own credit amount View credit packages

Express Pharma Private Limited — 360° Intelligence Report

Generated from MCA filings & public records
56/100
Trust Score
Moderate

Express Pharma Private Limited is assessed as Moderate with a Trust Score of 56/100. Express Pharma Private Limited is a private limited indian non-government company incorporated in 2005, operating in the Trading sector. Reported revenue has declined across its recent filed years. It reported a loss in its latest filed year. Based on MCA filings and public records, it currently shows a high compliance risk and high financial risk profile.

Report generated on 03 Jul 2026 from the latest processed filings. Express Pharma Private Limited snapshot & full profile →

Financial Health › Weak
Overall Assessment CautionWeakNeutralGoodStrong Good
Compliance › Weak

Automated indicators derived from public MCA / GST / EPFO records - not a credit rating, not investment, legal or financial advice. Spotted an inaccuracy? Report an error.

02

Score Card

Higher is safer · rule-based & explainable
Trust ScoreModerate
56/100
Overall counterparty trust - the headline number of this report.
Compliance ScoreCaution Indicated
43/100
Statutory standing - status, filings, auditor, MSME and litigation.
Financial Health ScoreCaution Indicated
40/100
Profitability, leverage and liquidity from filed statements.
Credit Risk ScoreModerate
50/100
Debt capacity, gearing and security cover for lenders.
Director Stability ScoreLow Risk
95/100
Board strength, DIN status, churn and network.
Growth ScoreCaution Indicated
40/100
Revenue, profit, asset and hiring momentum.
Distress ScoreCaution Indicated
35/100
Early-warning signals - higher means fewer warnings.
03

Financial Intelligence Dashboard

Standalone · 5 filed year(s)

Unlock the full 5-year financial dashboard with charts and year-wise figures.

Get full access

Scores and observations on this page are already computed from the real filings - only the underlying figures are locked.

04

Credit & Compliance Intelligence

Why the scores are what they are
Credit Risk Score: 50/100 Moderate
  • Negative operating earnings - debt service depends on external support.
  • No open charges - unencumbered balance sheet.
  • Working-capital cover adequate.

Charges position: 0 open (-) · 0 satisfied (-).

Compliance Score: 43/100 Caution Indicated
  • Company status is "Strike Off" - not Active.
  • Balance sheet slightly behind (Mar 2024).
05

Director Intelligence

Stability score: 95/100
NameDIN / PANDesignationAppointedTenureDIN status
JAYESH PRAVIN PANCHOLI 01234567 Director 01/04/2018 6 yrs Approved
KARL KEKI SURTY 01234567 Director 01/04/2018 6 yrs Approved
NIRAV NIRANJAN SHAH 01234567 Director 01/04/2018 6 yrs Approved
DEVINA NIRAV SHAH 01234567 Director 01/04/2018 6 yrs Approved
  • 4 directors on the board.
  • No disqualified or deactivated DINs.
  • Stable board - no exits in 3 years.
  • Average tenure above 5 years.
06

Ownership & Group Intelligence

As per FY 2017 annual return
Promoter holding
64.27%
Public / other holding
35.73%
Equity shares
12,45,67,890
Equity paid-up
124.5 cr
Promoters on record
4
Ultimate holding entity
-
Subsidiaries
-
Group entities
-
Capital events
-

Promoters hold a dominant controlling stake - exact percentages are part of the full report.

Full shareholding pattern, group structure & capital events →

07

Risk Intelligence Center

Growth 40 · Distress 35
Growth signals & trust indicators
Operating for 21+ years.
Distress signals & risk flags
Revenue declined year-on-year.
Losses deepening year-on-year.
Adverse company status: Strike Off.
Compliance score is weak (43/100).
08

Stakeholder Verdicts

Vendor · Banker · Investor
Vendor due diligence44/100
Caution indicated
Suitability as a supplier / customer counterparty.
  • Check the compliance flags before onboarding.
  • 3 distress signal(s) - see Risk Center.
  • Financial filings available for verification.
Banker assessment45/100
Mixed indicators - deeper appraisal suggested
Indicative lending comfort for banks, NBFCs and trade credit.
  • Debt capacity assessed from filed statements.
  • No existing security registered - first-charge position available.
  • Compliance gaps should be priced into terms.
Investor view44/100
Limited indicators at present
Growth quality and scalability through an investor lens.
  • No clear growth signals in the filed years.
  • Margin and return trends computable from filings.
  • Management team looks stable.
09

MCA Filings & Events Timeline

Latest 14 events
23 Sep 2024
Last AGM held
Annual general meeting
31 Mar 2024
Latest balance sheet
Filed with ROC
26 Nov 2021
Director ceased
KARL KEKI SURTY
19 Jul 2021
Director appointed
KARL KEKI SURTY (Director)
30 Dec 2020
Director ceased
JAYESH PRAVIN PANCHOLI
Director ceased
HIMANSHU BALMUKUND TRIVEDI
01 Jul 2020
Director ceased
INACINHO ESTELITO VALENTE ALEMAO
10 Feb 2020
Director appointed
JAYESH PRAVIN PANCHOLI (Director)
29 Sep 2018
Director ceased
DEVINA NIRAV SHAH
07 Jan 2018
Director ceased
NIRANJAN RAMANLAL SHAH
01 Nov 2017
Director appointed
DEVINA NIRAV SHAH (Director)
20 Feb 2017
Director ceased
ARUNIKA NIRANJAN SHAH
16 Mar 2005
Incorporated
Registered with Roc Mumbai
Director appointed
NIRAV NIRANJAN SHAH (Director)
10

Key Observations

Auto-generated from the data above
Revenue declined 38% over the last 4 financial year(s).
Net worth is positive.
4 active director(s) / partner(s); board looks stable and experienced.
Promoters hold a dominant controlling stake as per the FY 2017 annual return.
11

Peers & Related Companies

Full peer comparison →
CompanyCINLocation
Micro Max Media Private Limited U72900DL2000PTC105042 Delhi, Delhi, India
Shrishti Textiles Private Limited U17110MH2004PTC149213 Mumbai, Maharashtra, India
Minapan Marketing & Consultancy Private Limited U74900WB2014PTC201483 Kolkata, West Bengal, India
D.M. Finance & Leasing Private Limited U65921WB1991PTC053589 Kolkata, West Bengal, India
Sng Tradexim Private Limited U74999DL2010PTC200331 New Delhi, Delhi, India
Prakash Synergy Limited U45201CT2007PLC020380 Raipur, Chattisgarh, India
P2P Solution Private Limited U74900UP2010PTC040114 Lucknow, Uttar Pradesh, India
South Gujarat Papers Private Limited U21000GJ2010PTC060957 Vapi, Gujarat, India
12

Who Uses This Report

CA · CS · Banker · Investor · Vendor
Chartered Accountants (CA)

Verify Express Pharma Private Limited before audits and certifications: compliance score 43/100, filing history, auditor history and charge records in one place - instead of pulling each MCA form separately.

Company Secretaries (CS)

Track statutory health of Express Pharma Private Limited: ACTIVE compliance status, annual-return recency, director DIN status, board churn and the events timeline - the inputs for secretarial audits and due-diligence certificates.

Bankers & NBFCs

Current banker verdict: Mixed indicators - deeper appraisal suggested. Credit risk score 50/100, existing charge position and lender relationships - a first-pass credit memo before formal appraisal.

Investors & Analysts

Investor view: Limited indicators at present. Growth score 40/100, margin trends, ownership structure and peer set for Express Pharma Private Limited - screening before a deeper diligence.

Vendors & Procurement Teams

Vendor verdict: Caution indicated. Trust score 56/100, distress signals and MSME payment-delay disclosures - know whether Express Pharma Private Limited pays its suppliers before you extend credit terms.

Lawyers & Compliance Teams

Litigation footprint (no cases on record), regulatory flags, charge documents trail and director networks for Express Pharma Private Limited - groundwork for KYC, onboarding and disputes.

13

Frequently Asked Questions

Is Express Pharma Private Limited an active company?

Express Pharma Private Limited has MCA status “Strike Off” with a compliance score of 43/100 (Caution Indicated).

Is Express Pharma Private Limited financially healthy?

Express Pharma Private Limited has a Financial Health Score of 40/100 (Caution Indicated) based on its filed financial statements.

Should I do business with Express Pharma Private Limited?

Its overall Trust Score is 56/100 (Moderate). Vendor verdict: Caution indicated. Review the risk flags in the Risk Intelligence Center before deciding.

Who controls Express Pharma Private Limited?

Promoters hold a dominant controlling stake - exact percentages are in the full report. 4 active director(s) are on record.

Does Express Pharma Private Limited have loans or charges against its assets?

No charges are registered against this company - an unencumbered balance sheet.

Is Express Pharma Private Limited up to date with its ROC filings?

Balance sheet slightly behind (Mar 2024). Overall compliance score: 43/100 (Caution Indicated).

Is it risky to lend to Express Pharma Private Limited?

Its Credit Risk Score is 50/100 (Moderate). Banker verdict: Mixed indicators - deeper appraisal suggested.

Disclaimer: This report is generated automatically from MCA filings and public records as available in our system at the time of the last update. Scores, bands and verdicts are rule-based derived indicators of the underlying data - they are opinions generated by an algorithm, not statements of fact about the company, and are not credit ratings (within the meaning of SEBI regulations), audits, or investment, legal or financial advice. Verify from official sources and consult a qualified professional before any business, lending or investment decision. If you represent this company and believe any information is inaccurate or outdated, report it here and we will review promptly.